Cardiometabolic Effects of Denosumab in Premenopausal Women with Breast Cancer Receiving Estradiol Suppression: RCT
CONCLUSIONS: In premenopausal women receiving estradiol suppression, denosumab decreases some measures of fat mass with no detectable effects on other measures of body composition or metabolic parameters.PMID:38181438 | DOI:10.1210/clinem/dgae003 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - January 5, 2024 Category: Endocrinology Authors: Sabashini K Ramchand Rudolf Hoermann Shane White Belinda Yeo Prudence A Francis Cecilia L H Xu Jeffrey D Zajac Ego Seeman Mathis Grossmann Source Type: research
Denosumab use reduces risk of rheumatoid arthritis in patients with osteoporosis
CONCLUSIONS: Denosumab use reduces the risk of RA in patients with osteoporosis. Receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclast joint damage may be involved in the pathogenesis of RA during the preclinical stage.PMID:38179713 | DOI:10.55563/clinexprheumatol/3ohsj3 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - January 5, 2024 Category: Rheumatology Authors: Chun-Hsiung Chen Hsien-Tzung Liao Hung-An Chen Yi-Ning Yen Chen-Hung Chen Source Type: research
Cardiometabolic Effects of Denosumab in Premenopausal Women with Breast Cancer Receiving Estradiol Suppression: RCT
CONCLUSIONS: In premenopausal women receiving estradiol suppression, denosumab decreases some measures of fat mass with no detectable effects on other measures of body composition or metabolic parameters.PMID:38181438 | DOI:10.1210/clinem/dgae003 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 5, 2024 Category: Cancer & Oncology Authors: Sabashini K Ramchand Rudolf Hoermann Shane White Belinda Yeo Prudence A Francis Cecilia L H Xu Jeffrey D Zajac Ego Seeman Mathis Grossmann Source Type: research
Cardiometabolic Effects of Denosumab in Premenopausal Women with Breast Cancer Receiving Estradiol Suppression: RCT
CONCLUSIONS: In premenopausal women receiving estradiol suppression, denosumab decreases some measures of fat mass with no detectable effects on other measures of body composition or metabolic parameters.PMID:38181438 | DOI:10.1210/clinem/dgae003 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 5, 2024 Category: Cancer & Oncology Authors: Sabashini K Ramchand Rudolf Hoermann Shane White Belinda Yeo Prudence A Francis Cecilia L H Xu Jeffrey D Zajac Ego Seeman Mathis Grossmann Source Type: research
Cardiometabolic Effects of Denosumab in Premenopausal Women with Breast Cancer Receiving Estradiol Suppression: RCT
CONCLUSIONS: In premenopausal women receiving estradiol suppression, denosumab decreases some measures of fat mass with no detectable effects on other measures of body composition or metabolic parameters.PMID:38181438 | DOI:10.1210/clinem/dgae003 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - January 5, 2024 Category: Endocrinology Authors: Sabashini K Ramchand Rudolf Hoermann Shane White Belinda Yeo Prudence A Francis Cecilia L H Xu Jeffrey D Zajac Ego Seeman Mathis Grossmann Source Type: research
Efficacy and safety of denosumab versus zoledronic acid in OI adults: A prospective, open-label, randomized study
CONCLUSION: Denosumab effectively increases aBMD in OI adults, with similar efficacy to zoledronic acid. Long-term and large-sample studies are needed to confirm the anti-fracture efficacy and safety of denosumab in adult OI patients.PMID:38181430 | DOI:10.1210/clinem/dgae012 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - January 5, 2024 Category: Endocrinology Authors: Xiaoyun Lin Jing Hu Bingna Zhou Xiaojie Wang Qian Zhang Yan Jiang Ou Wang Weibo Xia Xiaoping Xing Mei Li Source Type: research
Denosumab use reduces risk of rheumatoid arthritis in patients with osteoporosis
CONCLUSIONS: Denosumab use reduces the risk of RA in patients with osteoporosis. Receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclast joint damage may be involved in the pathogenesis of RA during the preclinical stage.PMID:38179713 | DOI:10.55563/clinexprheumatol/3ohsj3 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - January 5, 2024 Category: Rheumatology Authors: Chun-Hsiung Chen Hsien-Tzung Liao Hung-An Chen Yi-Ning Yen Chen-Hung Chen Source Type: research
Denosumab versus pamidronate in the treatment of osteolytic bone metastases secondary to breast cancer: a multi-institutional analysis
CONCLUSION: Since neither therapy showed an increased risk in the adverse effects measured in this study, factors such as patient preference, financial costs, and additional side effects of each medication should be taken into consideration when choosing a therapy for bone metastases in patients with breast cancer.PMID:38174029 | PMC:PMC10761147 | DOI:10.1080/08998280.2023.2276623 (Source: Baylor University Medical Center Proceedings)
Source: Baylor University Medical Center Proceedings - January 4, 2024 Category: Universities & Medical Training Authors: Megan Bradley Mabry Nichols Brittany Miles Source Type: research
Denosumab versus pamidronate in the treatment of osteolytic bone metastases secondary to breast cancer: a multi-institutional analysis
CONCLUSION: Since neither therapy showed an increased risk in the adverse effects measured in this study, factors such as patient preference, financial costs, and additional side effects of each medication should be taken into consideration when choosing a therapy for bone metastases in patients with breast cancer.PMID:38174029 | PMC:PMC10761147 | DOI:10.1080/08998280.2023.2276623 (Source: Baylor University Medical Center Proceedings)
Source: Baylor University Medical Center Proceedings - January 4, 2024 Category: Universities & Medical Training Authors: Megan Bradley Mabry Nichols Brittany Miles Source Type: research
Denosumab versus pamidronate in the treatment of osteolytic bone metastases secondary to breast cancer: a multi-institutional analysis
CONCLUSION: Since neither therapy showed an increased risk in the adverse effects measured in this study, factors such as patient preference, financial costs, and additional side effects of each medication should be taken into consideration when choosing a therapy for bone metastases in patients with breast cancer.PMID:38174029 | PMC:PMC10761147 | DOI:10.1080/08998280.2023.2276623 (Source: Baylor University Medical Center Proceedings)
Source: Baylor University Medical Center Proceedings - January 4, 2024 Category: Universities & Medical Training Authors: Megan Bradley Mabry Nichols Brittany Miles Source Type: research
Denosumab versus pamidronate in the treatment of osteolytic bone metastases secondary to breast cancer: a multi-institutional analysis
CONCLUSION: Since neither therapy showed an increased risk in the adverse effects measured in this study, factors such as patient preference, financial costs, and additional side effects of each medication should be taken into consideration when choosing a therapy for bone metastases in patients with breast cancer.PMID:38174029 | PMC:PMC10761147 | DOI:10.1080/08998280.2023.2276623 (Source: Baylor University Medical Center Proceedings)
Source: Baylor University Medical Center Proceedings - January 4, 2024 Category: Universities & Medical Training Authors: Megan Bradley Mabry Nichols Brittany Miles Source Type: research
Denosumab versus pamidronate in the treatment of osteolytic bone metastases secondary to breast cancer: a multi-institutional analysis
CONCLUSION: Since neither therapy showed an increased risk in the adverse effects measured in this study, factors such as patient preference, financial costs, and additional side effects of each medication should be taken into consideration when choosing a therapy for bone metastases in patients with breast cancer.PMID:38174029 | PMC:PMC10761147 | DOI:10.1080/08998280.2023.2276623 (Source: Baylor University Medical Center Proceedings)
Source: Baylor University Medical Center Proceedings - January 4, 2024 Category: Universities & Medical Training Authors: Megan Bradley Mabry Nichols Brittany Miles Source Type: research
Denosumab combined with precision radiotherapy for recurrent giant cell tumor of the thoracic spine: a case report and literature review
Giant cell tumors of the spine have a high recurrence rate owing to their special anatomical site; hence, further treatment after recurrence is very challenging. Achieving effective tumor control and improving the long-term quality of life of the patients are the main treatment purposes to consider for recurrent giant cell tumors of the spine. A patient showing giant cell tumor recurrence of the thoracic spine after curettage received denosumab combined with precision radiotherapy, through which the tumor gained good control and the patient could regain normal functioning. A review of the relevant literature suggested that...
Source: Frontiers in Neurology - January 4, 2024 Category: Neurology Source Type: research
Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection
ConclusionsDenosumab-induced hypocalcemia is a prevalent adverse event, which occurs independently of the number of injections. However, severe hypocalcemia is a rare occurrence, and severe renal failure and nutritional status appear to be important predictive factors. Magnesium and phosphate might add value in the pre-injection risk assessment; however, this observation needs to be confirmed in larger cohorts. (Source: Osteoporosis International)
Source: Osteoporosis International - January 1, 2024 Category: Orthopaedics Source Type: research
